F10 and intracerebral hemorrhage: The effects of idarucizumab, the dabigatran-specific antidote, have been shown, but its effects on mortality have yet to be demonstrated.6 12 Furthermore, the recently published ANNEXA-I study showed no effect on clinical outcome as the positive effect of haemostatic control of andexanet alfa in FXa inhibitor-associated intracerebral haemorrhage was balanced with a higher risk of thromboembolic complications.17